New resource available view now
Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities
POTOMAC, MARYLAND – January 6, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,
New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer’s Drug Development
New Patent Expands IGC Pharma’s Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer’s Disease
POTOMAC, MARYLAND – October XX, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease,
POTOMAC, MARYLAND – December 15, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for
POTOMAC, MD December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease, today
POTOMAC, MARYLAND – December 09, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for
New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma’s Leadership in Alzheimer’s Innovation
POTOMAC, MARYLAND – November 25, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for